Pretreatment with Erythropoietin Attenuates Lung Ischemia/Reperfusion Injury via Toll-Like Receptor-4/Nuclear Factor-κB (TLR4/NF-κB) Pathway.
about
Pretreatment with Erythropoietin Attenuates Lung Ischemia/Reperfusion Injury via Toll-Like Receptor-4/Nuclear Factor-κB (TLR4/NF-κB) Pathway.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Pretreatment with Erythropoiet ...... actor-κB (TLR4/NF-κB) Pathway.
@en
Pretreatment with Erythropoiet ...... e Receptor-4/Nuclear Factor-κB
@nl
type
label
Pretreatment with Erythropoiet ...... actor-κB (TLR4/NF-κB) Pathway.
@en
Pretreatment with Erythropoiet ...... e Receptor-4/Nuclear Factor-κB
@nl
prefLabel
Pretreatment with Erythropoiet ...... actor-κB (TLR4/NF-κB) Pathway.
@en
Pretreatment with Erythropoiet ...... e Receptor-4/Nuclear Factor-κB
@nl
P2093
P2860
P921
P356
P1476
Pretreatment with Erythropoiet ...... Factor-κB (TLR4/NF-κB) Pathway
@en
P2093
P2860
P304
P356
10.12659/MSM.905690
P577
2018-03-01T00:00:00Z